comparemela.com

Latest Breaking News On - Asklepios group - Page 7 : comparemela.com

CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook

Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million. Core non-COVID-19 product sales were an estimated $7.6 million, .

United statesUnited kingdomState of new jerseyNew jerseyBruxelles capitaleCity ofMonmouth junctionJiny kimEric kimPhillip chanBuildout of the companyEuroelso congressMaterial commandEuropean unionUs armyBlood institute

CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook

/PRNewswire/ CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac.

United statesUnited kingdomState of new jerseyNew jerseyBruxelles capitaleCity ofJiny kimEric kimPhillip chanBuildout of the companyEuroelso congressMaterial commandEuropean unionUs armyBlood instituteNational heart

CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook

/PRNewswire/ CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac.

United statesUnited kingdomState of new jerseyNew jerseyBruxelles capitaleCity ofJiny kimEric kimPhillip chanBuildout of the companyEuroelso congressMaterial commandEuropean unionUs armyBlood instituteNational heart

CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany

MONMOUTH JUNCTION, N.J., May 2, 2022 /PRNewswire/ CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening condit.

United statesChristian steinerMaterial commandEuropean unionUs armyBlood instituteCytosorbents corporationNational heartAsklepios groupNational institutes of healthHuman servicesUs department of healthUs airPrnewswire cytosorbents corporationCorporate communicationsSorbents corporation

MediClin AG: Group sales for the 1st quarter of 2022 significantly above the previous year s figure

DGAP-News: MediClin AG / Key word(s): Quarterly / Interim StatementMediClin AG: Group sales for the 1st quarter of 2022 significantly above the previous year's figure 02.05.2022 / 12:40 The issuer is solely responsible for the content of this announcement.Offenburg, 2 May 2022Group sales for the 1st quarter of 2.

Baden wübergTino fritzAsklepios groupDistribution servicesInterim statementJoachim rammingCorporate newsRegulatory announcements

vimarsana © 2020. All Rights Reserved.